Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedernovartis.com
English RSS Feed
Get the latest updates from English RSS Feed directly as they happen.
Follow now 132 followers
Latest posts
Last updated 6 days ago
Novartis completes acquisition of Regulus Therapeutics
6 days ago
Novartis completes acquisition of Regulus Therapeutics arcticnovartis Wed, 06/25/2025 - 15:19 Read...
Novartis announces expiration of Regulus Therapeutics tender offer
7 days ago
Novartis announces expiration of Regulus Therapeutics tender offer arcticnovartis Wed, 06/25/2025 -...
Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer
9 days ago
Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer...
Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH
20 days ago
Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in...
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
30 days ago
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients...
Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis
about 1 month ago
Novartis Kisqali® reduces risk of recurrence in younger patients with early breast...
Novartis announces commencement of tender offer to acquire Regulus Therapeutics
about 1 month ago
Novartis announces commencement of tender offer to acquire Regulus Therapeutics arcticnovartis Tue...
Why advocating for your MS is so important
about 1 month ago
Why advocating for your MS is so important hajdola1 Thu, 05/22/2025 -...
New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
about 2 months ago
New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio...
Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben
about 2 months ago
Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge...
Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease
about 2 months ago
Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer...
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
about 2 months ago
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G)...